|
|
|
|
|
|||||||
|
Session 75
Poster Session
Resistance to Antiretroviral Chemotherapeutic Agents 4:30-6:30 pm 4E-F |
to view the poster for an abstract.| 552-T. | Influence of a Human Multidrug Resistance Genetic Polymorphism on Treatment Outcome in a Large Community-Based Cohort W. Dong, K. Chan, Z. Brumme, R. Hogg, M. V. O'Shaughnessy, and P. R. Harrigan* British Columbia Ctr. for Excellence in HIV/AIDS, St. Paul's Hosp., Vancouver, Canada
| ||
| 553-T. | Positive Selection of HIV-1 Protease (PR) Prior to the Advent of Protease Inhibitor-Based Therapy S. D. W. Frost*1, J. H. Condra2, D. D. Richman1, and A. J. Leigh Brown3 1Univ. of California, San Diego; 2Merck Labs., West Point, PA; and 3Univ. of Edinburgh, UK
| ||
| 554-T. | The Influence of Host HLA on Antiretroviral Drug Resistance Mutation in HIV-1 C. Moore, M. John, I. James, and S. Mallal* Ctr. Clin. Immunology and BioMed. Statistics, Perth, Australia
| ||
| 555-T. | Co-Existence and Co-Evolution of Viral Populations with Distinct Genotypes in Patients Failing Treatment with Protease Inhibitors C. Charpentier, D. E. Dwyer, D. Lecossier, F. Clavel, and A. J. Hance* INSERM U552, Paris, France
| ||
| 556-T. | HIV Drug Resistance Profiles and Clinical and Virologic Outcomes among HIV-Infected Subjects with Stable Detectable Plasma Viral Loads < 1000 Copies/mL for at least 12 Months E. P. Coakley*, J. P. Doweiko, N. A. Bellosillo, E. M. D'Agata, and M. A. Albrecht Beth Israel Deaconess Med. Ctr. and Harvard Med. Sch., Boston MA
| ||
| 557-T. | Hypersusceptibility to Protease Inhibitors Associated with Mutated Proteases at Codons 30 and 88 in Treated Patients V. Obry, E. Race*, M. Vray, J. L. Meynard, L. Morand-Joubert, D. Descamps, F. Brun-Vezinet, and F. Clavel for the ANRS 088 NARVAL Study Team INSERM U552, Paris, France
| ||
| 558-T. | Correlation of Phenotypic Resistance and Virologic Response to Indinavir/Ritonavir Boosted Regimens H. Rice*1, A. Zolopa1, M. Coram1, U. Murlidharan1, N. Shulman1, C. Vaamonde2, J. H. Condra3, N. S. Hellmann4, H. King4, and M. Bates4 1Stanford Univ., Palo Alto, CA; 2Cornell Univ., New York, NY; 3Merck Res. Labs., West Point, PA; and 4ViroLogic, Inc., South San Francisco, CA
| ||
| 559-T. | Quantitative Estimate of the Effect of Individual Baseline Mutations in HIV Protease on the Virologic Response to Lopinavir/Ritonavir Therapy in Heavily Antiretroviral-Experienced Patients J. Isaacson*1, D. Kempf1, V. Calvez2, I. Cohen-Codar3, D. Descamps2, E. Guillevic3, B. Bernstein1, E. Sun1, J. P. Chauvin3, and R. Rode1 1Abbott Labs., Abbott Park, IL; 2ANRS HIV Resistance Group AC11, Paris, France; and 3Abbott Labs., Rungis, France
| ||
| 560-T. | Influence of Genotypic Resistance on the Viral Load Response of 167 Patients on Lopinavir/r (LPV/r) including an Analysis of New Protease Inhibitor Resistant Mutations in 21 Patients who Failed M. Loutfy*1, C. Thompson1, M. Trpeski1, C. Kovacs1, A. Rachlis1, J. Goodhew1, G. Rubin1, K. Gough1,2, and S. Walmsley1 1Univ. of Toronto and 2St. Michael’s Hosp., Toronto, ON, Canada
| ||
| 561-T. | Impact of Gag Sequence Polymorphisms on HIV-1 Resistance to Protease Inhibitors L. Carron de la Carrière, F. Mammano, and F. Clavel INSERM U552, Hosp. Bichat, Paris, France
| ||
| 562-T. | Resistance to Tipranavir is Uncommon in a Randomized Trial of Tipranavir/Ritonavir (TPV/RTV) in Multiple PI-Failure Patients (BI 1182.2) R. Schwartz 1, P. Kazanjian2, L. Slater3, B. Hathaway4, M. Markowitz5, D. Wheeler6, M. Goldman 7, M. Drulak8, S. McCallister8, and D. Mayers*8 1Associates in Res., Fort Myers, FL; 2Univ. of Michigan Hlth. System, Ann Arbor; 3Univ. of Oklahoma Health Sci. Ctr., Oklahoma City; 4Eastern Carolina Univ. Sch. Med. Greenville, NC; 5Aaron Diamond AIDS Res. Ctr., Rockefeller Univ., New York, NY; 6 Infectious Disease Physicians Res. Ctr., Annandale, VA; 7Indiana Univ. Sch. Med., Indianapolis; and 8Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT
| ||
| 563-T. | Molecular Mechanism of I50V, I54L, and I54M Resistance to Amprenavir and Other HIV-1 Protease Inhibitors R. Xu, W. Andrews, A. Spaltenstein, D. Danger, W. Dallas, L. Carter, M. Hanlon, L. Wright, and E. Furfine* GlaxoSmithKline, Res. Triangle Park, NC
| ||
| 564-T. | Antiretroviral Resistance in ACTG 388 Participants with Virologic Failure A. Erice*1, H. Ribaudo2, L. M. Demeter3, S. H. Eshleman4, S. Hammer5, N. S. Hellmann6, and M. Fischl7 for the ACTG 388 Resistance Study Team 1Univ. of Minnesota, Minneapolis; 2Harvard Univ., Boston, MA; 3Univ. of Rochester Sch. of Med. and Dentistry, NY; 4Johns Hopkins Univ., Baltimore, MD; 5Columbia Univ., New York, NY; 6ViroLogic, Inc., South San Francisco, CA; and 7Univ. of Miami, FL
| ||
| 565-T. | Longitudinal Analysis of RT and Protease Mutations among Israeli Patients Infected with HIV Subtype C Z. Grossman*1, S. Maayan2, D. Auerbuch2, E. Sahar3, I. Levi4, M. Lorber3, G. Gottesman5, K. Rizenfeld6, M. Chowers5, Z. Kra-Oz2, E. Mendelson1, Z. Bentwich7, M. Elkan6, D. Engelhard2, S. Polak3, I. Yust8, and J. M. Schapiro9 for Israel Multi-Ctr. AIDS Study Group 1Publ. Hlth. Lab.; 2Hadassah Univ. Hosp.; 3Rambam Med. Ctr.; 4Sheba Med. Ctr.; 5Meir Med. Ctr.; 6Soroka Med. Ctr.; 7Kaplan Med. Ctr.; 8Soraski Med. Ctr.; and 9Natl. Hemophilia Ctr., Israel
| ||
| 566-T. | Evolution of Reverse Transcriptase and Protease Resistance Mutations in HIV-1-Infected Patients on Antiretroviral Therapy R. Kantor*1, R. Shafer1, D. Katzenstein1, S. Follansbee2, and J. Fessel2 1Stanford Univ., CA and 2Kaiser Permanente, San Francisco, CA
| ||
| 567-T. | Selection for Delavirdine (DLV) Resistance is not Associated with Loss of Nucleoside Analogue (NRTI) Resistance Mutations in Subjects with Non-Nucleoside Analogue (NNRTI) Hypersusceptibility -- Results from ACTG 359 R. Swanstrom*1, D. Katzenstein2, N. S. Hellmann3, S. A. Fiscus1, L. Petch1, H. Cheng4, R. Haubrich5, and R. Gulick6 1Univ. of North Carolina, Chapel Hill; 2Stanford Univ. Med. Ctr., Palo Alto, CA; 3ViroLogic, Inc., South San Francisco, CA; 4Harvard Sch. of Publ. Health, Boston, MA; 5Univ. of California, San Diego; and 6Weill Med. Coll. of Cornell Univ., New York, NY
| ||
| 568-T. | Choice of Co-Nucleoside Analog in d4T-Treated Subjects may Influence the Pattern of Thymidine Analog Mutations (TAMs) and Multi-Nucleoside Resistance Mutations (MNRs) L. Ross*1, Q. Liao1, K. Henry2, C. Cohen3, A. Hirani1, R. Fisher1, M. St. Clair1, and J. Hernandez1 1GlaxoSmithKline, Res. Triangle Park, NC; 2Regions Hosp., St. Paul, MN; and 3Comm. Res. Initiative, Boston, MA
| ||
| 569-T. | The Presence of Nucleoside Analogue Mutations (NAMs)iIs Highly Correlated with Reduced Susceptibility to all NRTIs J. M. Whitcomb, E. Paxinos, W. Huang, M. Maranta, K. Limoli, C. Chappey, N. T. Parkin, N. S. Hellmann, and C. J. Petropoulos* ViroLogic, Inc., South San Francisco, CA
| ||
| 570-T. | M184V Selection in Suppressed Subjects at Week 24 May Not Be Associated with Treatment Outcome (NZTA4002) J. J. Eron*1, D. McClernon2, A. Pierce2, G. Sawyerr2, H. Gao2, M. St. Clair2, J. Tolson2, G. Capuano2, J. Hernandez2, and J. Snidow2 1Univ. of North Carolina, Chapel Hill and 2GlaxoSmithKline, Res. Triangle Park, NC
| ||
| 571-T. | In Vitro Selection of the T215Y Mutation by Stavudine (d4T) in Viruses Carrying 215D/C from Drug-Naïve Persons G. García-Lerma*, H. MacInnes, S. Nidtha, D. Bennett, H. Weinstock, and W. Heneine CDC, Atlanta, GA
|
